Pharminent

‘Make in India’ strategy to kickstart domestic biomanufacturing, Biocon

A lack of investment and government support has stunted biomanufacturing in India, but Biocon says this will change through the country’s ‘Make in India’ programme. http://www.biopharma-reporter.com/Markets-Regulations/Make-in-India-strategy-to-kickstart-biomanufacturing-Biocon

Filed under: Emerging Markets